New drug shows promise for rare spine cancer
NCT ID NCT06787664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called BL-B01D1 in 27 adults with advanced chordoma, a rare bone cancer. The goal is to see if the drug can shrink tumors or slow disease progression. Participants receive the drug intravenously, and researchers monitor safety and effectiveness over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill stall advanced sarcomas?
- How do patients feel after Nose-Based brain surgery? new study aims to find out
- New gene therapy offers hope for advanced cancers
- Targeted drug shows promise for rare bone cancer
- New proton therapy could shrink skull tumor treatment to just 5 days
- Promising drug combo targets rare spine tumor